Although adding a PI3K inhibitor stabilized/delayed the progression of xenograft tumors, following treatment cessation, the tumor microenvironment boosted the expression of CD44v6 and Myc, resulting in tumor xenograft regrowth. Here, MYC is linked to neoplasm.